We used CB Insights' Investor Mosaic to rank healthcare venture capitalists. Orbimed Advisors, Alta Partners, and Versant Ventures topped the list.
With growth in healthcare IPOs, who are healthcare’s top institutional investors? Using our Investor Mosaic predictive algorithms, which consider factors such as past performance, network strength (who they know), selection aptitude and brand among other factors, we wanted to offer a statistical assessment.
For this analysis, we looked at all VC and PE investors with investments in at least 10 healthcare companies since 2008 and where the firm made more than 50% of their investments in the healthcare sector.
It is worth noting that due to this criteria of 50%+ of deals going to the healthcare industry, the focus of this analysis is on what can be considered mostly “pure-play” healthcare investors. Top-tier firms that are multi-sector (tech or energy + life sciences) were not considered. As a result, certain well-respected and successful life science investors such as as New Enterprise Associates, Atlas Ventures, Canaan Partners, Polaris Partners and Venrock among others were left out.
With these criteria, we are focused on 100 dedicated life science investors and first highlight who comes out on top and then analyze their areas of focus from a geographic and sector perspective.
Overall, OrbiMed Advisors ranked first, followed by Alta Partners and Versant Ventures. The full analysis includes:
- The top 20 Healthcare VCs
- Which Healthcare VCs have the best Networks?
- Which Healthcare VCs have the highest follow-on rate?
- Which geos are the top 20 investing in?
- Which sectors are the top 20 investing in?
OrbiMed Advisors is Top Healthcare VC
OrbiMed Advisors topped all other Healthcare VCs as the NY-based healthcare fund in our Investor Mosaic models. The firm has seen 5 exits in the past 2 months and over 10 since the beginning of 2013. Their most notable exits thus far this year come in the form of Saragon Pharmaceuticals, which was acquired for $1.7B by Genentech, and neuroscience-focused company SAGE Therapeutics, which went public in July 2014 at a valuation of $449.3M. Investor Mosaic scores for OrbiMed Advisors on the dimensions of network centrality and past performance also came in at the top of the list. Past performance is important in venture capital because of the phenomena of performance persistence in venture capital. In other words, in VC, past performance is indicative of future performance (it is not like public markets in this sense). Network centrality measures the firm’s connectedness with other firms. It is akin to Google PageRank for investors.
San Francisco-based Alta Partners and Menlo Park-based Versant Ventures rounded out the top 3. Alta Partners’ portfolio has been on a tear in 2014, as the life sciences fund has had 10 exits (9 IPO, 1 Acquisition) already this year, the largest of which was Kite Pharma’s June IPO which valued the drug development company at $632.4M.
The full ranking below with some of the funds’ most recent notable exits. Of note, all but 4 of these investors have had multiple Healthcare exits in 2014.
OrbiMed Advisors wins on Network Centrality
The network of venture capital investors is incredibly important both for dealflow, deal syndication and in getting access to information. Investor Mosaic models quantitatively score an investor’s network utilizing what we call a network centrality score. OrbiMed Advisors led all Healthcare VCs in network centrality. MPM Capital, SF Capital Partners, and Iroquois Capital Group are among the fund’s top follow-on investors. Versant Ventures and Domain Associates rounded out the top 3. Versant Ventures’ top follow-on investors include ARCH Venture Partners, and Bay City Capital, while Domain Associates, the Princeton-based VC firm which has recently invested in TWELVE, Benvenue Medical, and Sebacia counts Highbridge Capital Management, Deerfield Management, and Silicon Valley Bank among its top follow-on investors.
Trio of VC investors tie for best follow-on rate
Life Sciences Partners, Venture Investors, and TPG Biotech led all Healthcare VCs in terms of follow-on rate. Follow-on rate is an important measure of firm quality as the ability to assist portfolio companies with follow-on financing.
Life Sciences Partners is an early to mid-stage focused life sciences venture capital firm based in Amsterdam while Venture Investors is a VC firm with offices in Ann Arbor, MI and Madison, WI that leverages nearby research institutions to invest in Midwest companies, including Ohio-based Aerpio Therapeutics and Juventas Therapeutics.
Notable TPG biotech investments to receive follow-on capital include Ultragenyx Pharmaceutical, Novasom, and Auxogyn.
California captures 41% of deals
California captured 41% of Healthcare deal activity among the Top 20 healthcare investors with the Golden State seeing over 300 deals with participation from the top 20. Within California, some of the investments which featured multiple Top 20 VCs included Kalidex Pharamaceuticals‘ $45M Series A (MPM Capital, OrbiMed Advisors, Domain Associates, Frazier Healthcare, New Leaf Venture Partners) as well as Principia BioPharma which saw participation in its Series A and B rounds from Morgenthaler Ventures, OrbiMed Advisors, and New Leaf Venture Partners.
International investments made up 8% of all deals from the Top 20. These investments featured the foreign Healthcare VCs in the Top 20 which included Morningside Group (Hong Kong) and Abingworth (UK) as well as US-based investors OrbiMed Advisors, Novartis Venture Funds, SV Life Sciences, and others.
Medical Devices are 1/3 of deal share
Medical Devices & Equipment captured over one-third of all deals within Healthcare from the Top 20 since 2011 as they participated in rounds totaling over $4B across over 270 deals. Cardiac defibrillator company Cameron Health’s $107M financing round was the largest among the top 20 investors within the Medical Devices space, seeing participation from Delphi Ventures before the company was acquired by Boston Scientific Corporation for $1.3B in 2012.
Biotechnology and Drug Development were second with a 20% deal share among the Top 20. ARCH Venture Partners has invested in two of the largest deals in biotech including Juno Therapeutics. Juno is developing cancer technology that will genetically modify patients’ white blood cells to attack cancerous tumors. ARCH Venture Partners has invested in every round the company has raised thus far, including a $134M Series B on August 5th, 2014 which saw participation from Venrock, Bezos Expeditions, and Alaska Permanent Fund, as well as a $120M Series A financing that took place just 8 months prior in December 2013. As other companies aim to get the CART technology to market, this could be a pivotal time for Juno as well as competitors Kite Pharma and Novartis.
For further analysis around healthcare investments check out our posts on Pre-IPO healthcare funding, Massachusetts healthcare funding, and healthcare CVC funding and exits.
To track healthcare investors and emerging life science companies, create a free account below to the CB Insights venture capital database.
photo credit: 401kcalculator.orgIf you aren’t already a client, sign up for a free trial to learn more about our platform.